The growing consumption of drugs and other numerous factors relates to the increasing incidence of polypharmacy. The proportion of patients currently treated with 5 or more medicines at the elderly population in particular is 30-60% of patients. Repeatedly has been proven the dependence between the number of concomitant drugs and occurrence of adverse effects, patients requiring hospitalization, or incidence of moderate and serious drug interactions. Some works show that it is possible to satisfactorily address the issues of polypharmacy, but it requires great courage and an interdisciplinary approach involving modern information technology.
- MeSH
- lékové interakce * MeSH
- lidé MeSH
- polypharmacy * MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- anglický abstrakt MeSH
- časopisecké články MeSH
Many patients with diabetes mellitus are treated by various medicinal products, which can in some cases lead to drug interaction. In this paper drug interactions of antidiabetics are summarised and most important drug interactions of other drugs frequently prescribed to diabetics are mentioned: drugs acting on the renin-angiotensin system and statins.
- MeSH
- diabetes mellitus farmakoterapie MeSH
- hypoglykemika terapeutické užití MeSH
- komplikace diabetu farmakoterapie MeSH
- lékové interakce * MeSH
- lidé MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- anglický abstrakt MeSH
- časopisecké články MeSH
- přehledy MeSH
- Názvy látek
- hypoglykemika MeSH
A comparison of effectiveness of TNF antagonists adalimumab, infliximab and etanercept in the treatment of rheumatoid arthritis (RA) was made, which was derived from studies provided abroad based on routine clinical practice. The calculation of cost-effectiveness of each TNF antagonist for Czech Republic was made on the basis of Dutch DREAM registry of patients with RA (Kiewit et al, 2008). The prices of therapy of all three TNF antagonists are similar in the first year of treatment of patients with average weight, in the second year the price of infliximab is lower, but only in the case of patients where the doses do not reach 4 amp. of infliximab. Clinical effectiveness was evaluated in DAS28 and HAQ units. Cost-effectiveness of all TNF antagonists was similar, when 2 amp. of infliximab per dose phycician considered sufficient, but when patients were given higher doses of infliximab the trend to lower cost-effectiveness of infliximab compared to adalimumab and etanercept was observed.
- MeSH
- adalimumab MeSH
- analýza nákladů a výnosů MeSH
- antirevmatika ekonomika terapeutické užití MeSH
- etanercept MeSH
- humanizované monoklonální protilátky MeSH
- imunoglobulin G ekonomika terapeutické užití MeSH
- infliximab MeSH
- lidé MeSH
- monoklonální protilátky ekonomika terapeutické užití MeSH
- receptory TNF terapeutické užití MeSH
- revmatoidní artritida farmakoterapie ekonomika MeSH
- TNF-alfa antagonisté a inhibitory MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- anglický abstrakt MeSH
- časopisecké články MeSH
- přehledy MeSH
- Geografické názvy
- Česká republika MeSH
- Názvy látek
- adalimumab MeSH
- antirevmatika MeSH
- etanercept MeSH
- humanizované monoklonální protilátky MeSH
- imunoglobulin G MeSH
- infliximab MeSH
- monoklonální protilátky MeSH
- receptory TNF MeSH
- TNF-alfa MeSH
